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3. Introduction 
Juvenile Dermatomyositis (JDM) is a very rare, presumably autoimmune disease of 
childhood characterized by proximal muscle weakness and a classical rash. Being a 
systemic vasculopathic disease, other organs like the lungs, heart and 
gastrointestinal tract can also be affected (1).  
Before 1960, there was no effective treatment for JDM. A review from 1964 
introduced the “rule of thirds” for untreated JDM (2), 1/3 of the patients died, 1/3 
evolved serious functional disability and 1/3 recovered. After first corticosteroids and 
gradually other immunosuppressive agents were introduced in the treatment from the 
early 1960th, the mortality rate decreased to < 5 % in the new millennium. However, 
even though the survival rate is increasing, many patients still develop calcinosis and 
other complications. Thus, there has been an increasing interest in long-term 
outcome of JDM (3).   
At the time our study was initiated, data on long-term outcome was scarce, 
and we therefore had no good answer to the question frequently asked by the 
parents of JDM patents: “What is the prognosis of my child?” Working a period as a 
clinician at the Department of Pediatric Rheumatology at Oslo University Hospital 
(OUH), I developed an interest for this disease. Even though being extremely rare, it 
is said about JDM: “if you have ever seen a patient, you never forget” and “the clinical 
manifestations in JDM are some of the most interesting in all pediatric medicine” (4). 
The few patients I saw during this period, I certainly did not forget, and I developed 
and eager to find some answers to this important question.  
During the 1990th, tools for measuring myositis outcomes had been developed 
by two international collaborations, making it possible to measure outcomes utilizing 
standardized methods. This is an important basis for the possibility of comparing 
myositis studies addressing outcomes.  
In Norway, most JDM patients have been treated at the department of 
Rheumatology, OUH (before 2000 being Oslo Sanitetsforenings Revmatisme-
sykehus, OSR) or at the pediatric departments of the other major hospitals in 
Norway. Also, thanks to the Norwegian population register, we have unique 
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opportunities to trace former patients who are no longer in the hospital system, being 
an important premise for this doctoral thesis.  
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4. Background 
Idiopathic inflammatory myopathies 
JDM belongs to the idiopathic inflammatory myopathies (IIM), being chronic immune 
mediated muscle diseases. Adult onset IIM can be classified in several 
clinicopathologic subsets. The same subsets can be applied in juvenile IIM, but the 
frequency distribution for the various subsets differ between juvenile and adult onset 
disease (5). These subsets are as follows (modified from Rider) (5):
 Dermatomyositis (DM) 
 Polymyositis (PM) 
 Overlap myositis  
 Inclusion- body myositis  
 Amyopathic dermatomyositis 
 Other types (e.g. cancer associated myositis, orbital myositis, granulomatous 
myositis, eosinophilic myositis etc). 
Unlike in adults, DM is the far most common type of juvenile IIM, representing 85-
95% of the cases (6). The age limit for juvenile vs. adult onset DM is not clearly 
defined; 16-20 years have been used in different studies, although 18 years seems to 
me most common (5). Juvenile PM (which lacks the classical rash) is much rarer, and 
constitutes ~8% of juvenile IIM cases (7) and over lap myositis (myositis associated 
with other autoimmune diseases) ~7% (8;9). Amyopathic dermatomyositis is rare in 
children (1). The other forms listed above, are extremely rare or absent in the 
pediatric population.  
Diagnostic criteria for dermatomyositis and polymyositis 
In 1975, Bohan and Peter developed diagnostic criteria for dermatomyositis and 
polymyositis (10;11)(table 1). The Bohan and Peter criteria are the preferred criteria 
used for diagnostic work-up in JDM. They are also widely applied in research, and 
are recommended used as inclusion criteria for enrollment of adult and juvenile PM 
and DM patients into clinical trials (12). However, the specificity and sensitivity of 
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these criteria have never been tested in the juvenile population (13). Many 
investigators think the criteria are outdated in pediatric practice, since performance of 
muscle biopsies and electromyography often is avoided in classical JDM cases (14). 
Being more that 30 years old; these criteria do not include advantages in diagnostic 
procedures like magnetic resonance imaging (MRI) of muscles or myositis specific 
autoantibodies (MSAs). Also, the degree of abnormality required for each criterion is 
not specified (e.g. muscle enzymes). Several attempts have been made in order to 
develop new classification and diagnostic criteria for inflammatory myopathies (14-
16), but none of these are internationally accepted. However, an international effort 
to develop new classification criteria for IIM is now under way (17;18).  
 
Table 1. Bohan and Peter Criteria (adapted from Bohan and Peter) (10;11) 
1. Characteristic cutaneous changes (e.g. heliotrope, Gottron) 
2. Symmetric, often progressive weakness of proximal musculature 
3. Elevation of the serum level of one or more of the muscle enzymes, creatine Kinase (CK), 
lactate dehydrogenase (LD), aspartate aminotransferase (ASAT) or aldolase 
4. Electromyographic (EMG) changes characteristics of myopathy and denervation 
5. Muscle biopsy documenting histological evidence of perifascicular atrophy, perisvascular 
inflammatory infiltrates and necrosis of muscle fibers 
Definite DM requires the skin criterion (criterion 1) and 3 of the muscle criteria (criteria 2-5); whereas 
probable DM requires the skin criterion and 2 muscle criteria.  
Exclusion criteria: The diagnosis of PM/DM requires that all other forms of myopathy (e.g. infectious,
metabolic, endocrine disorders and dystrophic myopathies) are excluded by appropriate clinical, 
laboratory, genetic or pathologic techniques.  
 
By consensus, a probable or definite adult or juvenile DM is recommended for 
inclusion in clinical trials (12). 
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Epidemiology
JDM is a very rare disease; the most reliable data for annual incidence (1.9 - 3.2 per 
million children) is reported from population based studies in UK and USA (19;20) 
(table 2). Data from Scandinavian countries is limited by inclusion of only 4-13 cases 
(21-23). There is no reliable data for prevalence. A female predominance has been 
reported from the Western world (60-83% females) (table 2), but has not been found 
in studies from Japan and Saudi Arabia (40-42% females) (24;25). Some reports 
suggest that the female dominance is lower in younger age groups (26). The average 
age at onset is 7 years (13;19). In a recent study, 25% of JDM patients were < 5 
years of age at disease onset (27). Even though an overrepresentation of black 
children has been reported from the UK (28), this was not found in USA (20), were 
the annual incidence estimates were comparable for whites and blacks (3.4 and 3.3 
per million children), but slightly lower in Hispanics (2.7 per million children) (20).  
 
Table 2: Juvenile IIM epidemiological studies* 
 Oddis (29) Symmons (19) Mendez (20) Fujikawa (30) 
Year 1963-1982 1992-1993 1995-1998 1997 
Country USA United Kingdom USA Japan 
Source Hospital 
based 
Practitioners 
based 
2 US national 
registers 
Hospital based 
Cases 
included 
21 JDM 47 JDM 276 JDM 320 IIM 
Age limit, 
years 
<15 < 16 2-17  
Incidence/mill 
(95 % CI) 
2.5 1.9 
 (1.4-2.6) 
3.2  
(2.9-3.4) 
1.6 
Female %  83% 70%  
 
*Only studies with at least 20 JIIM cases are included 
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Pathogenesis
The etiology of JDM is relatively unknown. A working hypothesis is that in genetically 
susceptible individuals, environmental factors may trigger immune dysfunction and 
specific tissue response in small vessel endothelium (in skin, muscle and other 
organs)(31).  
The strongest genetic associations for autoimmune diseases, including JDM, 
are with genes in the human leukocyte region (HLA) in the major histocompatibility 
complex on chromosome 6 (7). In this region, multiple genes coding for proteins 
central to the immune system are clustered (including HLA class I, II and III 
molecules)(32). Alleles at the 8.1 ancestral haplotype (HLA-B*08-DRB1*0301-
DQA1*0501), has been described as a strong immunogenetic predisposing factor for 
many autoimmune diseases in Caucasians, including adult DM and JDM (32-35). In 
JDM, an additional risk factor (DQA1*0301 allele) and several protective factors have 
been identified (36). However, HLA-DRB1 allele carriage frequencies have not 
previously been described in Scandinavian JDM patients.  
Several other polymorphic loci have been associated with severe disease. 
Tumor necrosis factor alpha (TNF-) 308A polymorphism has been associated to 
calcinosis, ulcerations and disease chronicity (37), and also small vessel occlusion 
(38). An Interleukin-1 polymorphism confers additional risk for development of 
calcinosis (39). 
In two studies, most children had symptoms consistent with infection 3 months 
before onset of symptoms, suggesting an infectious trigger (27;40). Also 
geographical or seasonal clustering within the onset of the disease suggests 
environmental triggers. However, no specific infectious agents have been found in 
case control studies (41). Also, there are reports of JDM onset after vaccines, drugs 
and UV light exposure (31). 
JDM is thought to be a vasculopathic condition (42). The small vessel 
endothelium (capillaries, venules and small arteries) in muscles, skin and other 
organs are important targets for the immune response (which involves humoral, 
cellular and innate immunity, and will not be further discussed) (1). The result of this 
process is swelling of the endothelium, causing necrosis, capillary thrombosis and 
thus obliteration of the lumen, which may lead to ischemia. This immune mediated 
endotheliopathy (or vasculopathy), is thought to be more common than true 
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vasculitis. These changes can be studied in the nailfold region (enlarged loops, with 
capillary drop outs) and probably reflect what may be occurring in small caliber 
vessels in other organs. In the skin, these changes lead to variety of rashes, and in 
the gastrointestinal tract may cause pain, infarction and perforation (1;31;43).  
In muscle biopsies, this endothelium swelling and obliteration of the lumen can 
be observed. The vasculopathy is thought to be the reason for the typical peripheral 
fascicular atrophy often seen. In more severe cases, muscle cell necrosis may occur, 
with minimal or no inflammation (inflammation most often seen in the perimysium and 
perisvascular) , probably because of an ischemic myopathy rather than immune 
attack on muscle cells (43).  
The calcification in JDM is dystrophic (at sites of injured tissue with normal 
serum calcium and phosphorus levels)(44), and is found in muscles severely 
affected. Increased level of TNF- has been associated with calcinosis (TNF- 308A 
polymorphism). It is therefore believed that underlying inflammation might contribute 
to development of calcinosis (37), whereas calcium deposition previously was 
thought to be part of the scarring process (45). 
Autoantibodies 
Autoantibodies in IIM can be divided into myositis-specific antibodies (MSA), which 
are relatively specific to IIM, and myositis-associated antibodies (MAA), which are 
also seen in over lap syndromes or other autoimmune diseases. The MSA includes 
the antisynthetase antibodies (anti Jo-1 being most common), anti SRP and anti Mi-
2, whereas examples of MAA are anti-Ku, anti-PMScl and anti-Ro (31). In adult DM 
and PM, MSAs are seen in almost 50% of the patients (46;47). At the time our study 
was initiated, MSA had been found in 4-11% of juvenile IIM patients, most commonly 
Mi2, but also SRP and anti-Jo1 had been described (5;48). MSA and MAA are 
associated with specific clinical features (e.g. antisynthetase antibodies and 
interstitial lung disease), immunogenetics and prognosis (35). Also, anti nuclear 
antibodies (ANA) with uncertain specificity had been found in up to 70% of JDM 
patients (49).  
Clinical manifestations, disease course and treatment 
The most common symptoms in JDM are progressive proximal and axial muscle 
weakness in addition to a classical, often pathognomonic rash (heliotrope rash, 
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Gottron’s papules). Other frequent skin involvement includes periungual and malar 
erythema, and less commonly skin ulcers. Other symptoms are variable. 
Constitutional symptoms (fever, lethargy) can be seen early in disease course. Other 
organs as the joints (arthralgia, arthritis, contractures), lungs (dyspnoea, interstitial 
lung disease), heart (pericarditis, myocarditis), and gastrointestinal tract (dysphagia, 
bleeding, perforation), can also be affected (1). Lipodystrophy, being fat loss 
associated with metabolic alterations, is seen in 10-40% (50). As opposed to in adult 
onset IIM, malignant disease is very rare in JDM and equals the incidence in the 
general pediatric population(51).  
A hallmark of JDM is calcinosis, which is described in 10-50% of patients 
(9;45;52;53), most often 1-3 years after diagnosis (range 0-20 years) (45;52). Four 
different patterns have been recognized: 1) cutaneous or subcutaneous plaques or 
nodules, 2) deposits that extend to muscles 3) along facial planes and 4) widespread 
calcium exoskeleton (54). Dependent on distribution, calcinosis may induce 
contractures (if crossing joint margins), pain due to nerve entrapment, ulcerations or 
inflammatory reactions during active deposition, or be infected (45;55). Calcinosis is 
known to be associated with functional disability (52).  
JDM disease course is heterogenic; 3 distinctive disease courses have been 
recognized (52;56)  
 Monocyclic course: permanent remission within 2-3 years (25-37%) 
 Polycyclic course: periods of remission followed by relapse (11-27%) 
 Chronic, continues course: persistent disease for longer than 2-3 years (44-
52%) 
Various studies have reported on disease course, but it should be noted that the 
definitions have varied (45;57); and is complicated by the lack of an established 
definition for remission. Some authors also use the terms unicyclic and non-unicyclic 
(37;58).  
 The aims of medical treatment are to control disease activity, prevent 
mortality and reduce long-term disability and complications. Since there are no 
randomized controlled trials (RCT) available, regimes are based on clinical 
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experience, uncontrolled retrospective reports and open- label prospective case 
series (5;59). First line treatment has since early 1960th been high-dose, oral 
corticosteroid therapy (1-2 mg/kg). In many centers, iv methylprednisolone (10-30 
mg/kg/pulse) and and/or methotrexate (0.4-1 mg/kg/week) are added as first line 
agents, due to data suggesting that such regimes may reduce complications and 
increase the chance of early remission (60) (even though these data are based on 
historical reference groups). Hydroxychloroquine is used, especially to control 
rashes. For patients who do not adequately respond to first line treatment, other 
adjunctive steroid-sparing immunosuppressive therapies may be added (e.g. 
cyclosporine, azathioprine, cyclophosphamide, intravenous immunoglobulin, anti-
TNF agents and tacrolimus). Importantly, and contrary to what was previously 
believed, early physiotherapy seems to be safe, also in patients with active myositis. 
This is supported by a study using MRI scans before and after a moderate exercise 
program, indicating no evidence of increased muscle inflammation after exercise 
(61).  
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Outcome 
Outcome assessment 
In 2001, the World Health Organization provided a framework for measuring health 
and health related domains, the International Classification of Functioning, Disability 
and Health (62). Disability is an umbrella term for impaired body structure and 
function, limitations in the ability to perform activities in daily life, and restrictions in 
the ability to participate in society (63;64). When applied in myositis research, 
examples of measures of body function and structures are Manual Muscle test 
(MMT) and MRI findings, whereas an example of a measure of limitation of daily 
activities and restrictions to participate in society is the short form 36 (SF-36)(64).  
Given the poor prognosis for untreated JDM, studies published prior to the 
1960th, focused primarily on mortality, considerable disability and to a lesser extent 
on complications like calcinosis. With more children surviving the disease, the focus 
of interest shifted from survival towards long-term morbidity like calcinosis, and 
functional outcomes (3;65). However, myositis outcome research has been limited by 
the lack of established outcome measures. An international effort defining such 
measures has recently been carried out by two international collaborative 
organizations. The International Myositis Assessment & Clinical Studies Group 
(IMACS) and the Pediatric Rheumatology International Trials Organization (PRINTO) 
have, by different processes, defined 3 important domains for assessment in 
therapeutic trials and natural history clinical research (66;67). These domains are: 
disease activity (potentially reversible with treatment), disease damage (irreversible 
changes in anatomy, physiology or function) and health related quality of life. The 
proposed core sets for these domains, are presented under Methods section page 27 
(table 4).  
Outcome studies 
At the time our study was initiated, quality data on long term outcome was limited (3). 
It was known that the outcome had improved considerable since the “rule of thirds” 
for untreated JDM was introduced (1/3 died, 1/3 evolved severe functional 
impairment and 1/3 recovered) (2). Since the introduction of corticosteroid therapy in 
the 1960th, the mortality rate decreased from 9% in the early 1980s (3), and in 2000-
2004 reported to be 0-6 % (table 3). However, as shown in table 3, most of these 
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studies are retrospective and include few patients. Some of them also include 
patients being followed for less than 2 years (patients early in disease course) and 
these studies have the lowest reported frequency of calcinosis (68;69). Some studies 
refer to disease course or remission, but the definitions of these terms vary, and 
make the results hard to compare. None of the studies have measured disease 
activity at follow-up by validated tools. Also, data on muscle weakness and functional 
disability are hard to compare, due to lack of standardized measures. Only two small 
studies have included follow-up examination (70;71). 
 
Table 3. JDM outcome studies published before 2005* 
 n Methods Follow-up 
yrs (range) 
Death Functional 
disability 
Disease 
course 
Weakness / 
rash 
Calcinosis 
Bitnum (2) 
1964 
168 Review of 
published cases 
 34% 33% 
(“crippled”) 
   
Pachman (72) 
1980 
21 Prospective Mean 4 
(0.5-11) 
0.5% 10%   43% 
Chalmers (70) 
1982 
17 Follow-up 
examination 
Mean 18.5 
(8-36) 
 12%  35% / 41% 41% 
Bowyer (45)  
1983 
47 Retrospective Mean 5.5 
(2-16) 
2.1% 38% Monophasic: 
23% 
 51% 
Miller (57) 
1987 
39 Retrospective + 
questionnaires 
Mean 9 
(3-22) 
26% 12%  
(of 
survivors) 
Mild:  
15% 
13% / - 30% 
Collison (71) 
1998 
12 Follow-up 
examination* 
10 
(2-29) 
 25%  67% / 78% 
 
 
Ng (73) 
1998 
33 Retrospect + 
questionnaires 
Mean 6.2 
(2-18) 
0 Monocyclic 
42% 
 15% 
Tabarki (74) 
1998 
36 Retrospective Mean 4.9 
(2-13) 
 22% Monophasic 
39% 
 42% 
Shehata (24) 
1999 
25 Retrospective Mean 4.5 
0.5-9 
0   48% / - 40% 
Huber (52) 
2000 
65 Questionnaires 
+ telephone 
interview 
Med 7.2 
(3-14) 
1.2% 28% (child 
HAQ>0) 
Monocyclic 
37% 
23% / 40% 
 
 
34% 
 
Sallum (68) 
2002 
35 Prospective + 
retrospective 
Mean 3.5  
(1-11) †  
6%  Remission 
59% 
-  /11% 14% 
Singh (69) 
2004  
33 Retrospective Mean 4.2 
(0.6-13) ‡ 
6%  Monocyclic 
73% 
21% / 15% 27% 
 
*Only studies with mean/median (med) follow-up time at least 3 years are included; all studies are hospital based.  
†15% followed  2 years, ‡ 30% followed  2 years. 
In 2000, the result from a Canadian multi-center inception cohort was 
published (52)(table 3). Out of 80 identified patients, 65 (81%) could be contacted; 
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patients were interviewed by telephone or in person, and completed the Childhood 
Health Assessment Questionnaire (child HAQ). Calcinosis was found in 34%, 35% 
were still on immunosuppressive medication, but 72% had no physical disability 
measured by child HAQ. This study, although limited by lack of follow-up 
examination, represented a step forward in describing JDM outcomes. 
Organ damage  
Since many organs potentially can be involved in the IIM, a global, comprehensive 
tool for measuring damage in 11 organs and systems, the myositis damage index 
(MDI) (66;75) was developed by IMACS in the 1990th, using the pattern of the 
SLICC/ACR damage index for systemic lupus erythematosus (76). Damage is 
defined as persistent or permanent changes in anatomy, physiology, and function, 
being a result of previous active disease, complications of therapy or comorbid 
conditions (66). When our study was initiated, the MDI was still under validation, and 
no data on organ damage applying the MDI tool in a JDM cohort was available.  
Muscular outcome 
JDM causes inflammation in skeletal muscles (disease activity) which may lead to 
muscle scarring and atrophy (disease damage). Since these processes affect muscle 
strength and endurance, impairments of these are important outcome measures in 
IIM (1;64;77) and are included in both disease activity and damage domains (67;75). 
The manual muscle test (MMT) measures peak muscular force and is the most 
commonly used primary outcome measure in IIM therapeutic trials (66). There are 
different versions of MMT available, including 24 muscle subsets tested bilaterally 
and 8 muscle version tested unilateral (MMT-8), also both 0-5 and 0-10 grading scale 
have been used (12;78). At the start of our study, the MMT-8 version was 
recommended by IMACS for research purposes, since it compared with the 24 
muscles version was less time consuming, and seemed to perform similar (78;79). 
The Child Myositis Assessment Scale (CMAS) is a performance- based instrument 
developed to evaluate muscle strength, endurance and physical function in juvenile 
IIM (80;81).  
 MRI of proximal thigh muscles is a method that can distinguish between 
muscular disease activity and damage (66). Short tau inversion recovery (STIR) or 
T2 weighted fat suppressed series are useful for detecting inflammation in muscle, 
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subcutaneous tissue and skin (increased water content) (82-84) whereas T1 
weighted series assesses muscle fatty infiltration and atrophy and subcutaneous 
atrophy (84-86). Being a non-invasive test that visualize many muscle groups at a 
time, MRI is thought to have a role in detecting long term muscular complications of 
JDM (87). However, due to high costs and limited availability worldwide, MRI is not 
included in the core sets for disease activity or damage (66;67). 
When our study was initiated, muscle weakness had been described in ~ 35% 
in two small studies which included follow-up examination (70;71), and self-reported
muscle weakness (by patients or parents) in 23% of 65 patients (52)(table 3). 
However, no JDM outcome studies had utilized MMT or CMAS after long term follow-
up. MRI detected fatty infiltration, atrophy and calcinosis/fibrosis had been reported in 
3 small series, including 4-19 patients after 4-18 years of follow-up (71;86;88).  
Pulmonary outcome 
In adult polymyositis and dermatomyositis, pulmonary involvement, especially 
interstitial lung disease (ILD) is an established complication, resulting in high 
morbidity and mortality (89). The presence of antisynthetase antibodies is an 
important risk factor for ILD in IIM, and is seen in 30-40% of adult IIM patients vs. 
only 1-3% of JDM patients (90). However, serious and fatal lung involvement in JDM 
has been described in case reports (91;92). Restrictive ventilatory defects and 
reduced diffusion capacity of carbon monoxide (DLCO) have previously been 
described in two small JDM series (72;93). Also, calcinosis can be confined to the 
chest wall, and thus lead to restrictive ventilatory defects (94).  
The preferred method for assessing restrictive ventilatory defects (small lung 
volumes) is body plethysmograph assessed total lung capacity (TLC). High resolution 
computed tomography, is a sensitive method to detect pulmonary disease, as ILD 
(95), and can also detect calcinosis in the chest wall. ILD confirmed by HRCT, has 
been described in a 5/10 patients with severe JDM (96). However, the prevalence of 
pulmonary function impairment and HRCT abnormalities in unselected JDM patients 
have never been investigated, and no controlled studies are available.  
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Prognostic factors for unfavorable outcomes 
When our study was initiated, delay in treatment and inadequate treatment, had been 
recognized as risk factors for calcinosis and an unfavorable functional outcome 
(45;53;74). Also, a chronic disease course had been associated with physical 
disability (52), but no relation was found between severity at onset and outcomes. In 
most studies, patient characteristics like age at disease onset, gender and ethnicity, 
was not related to physical disability or calcinosis (45;72;97). On the other hand, 
Huber et al found that females had more physical disability (higher child HAQ scores) 
(52). Although rare in JDM, certain MSA (like anti-Jo1) are risk factor for severe 
disease (5). In a small longitudinal study of 12 JDM patients, ANA was associated 
with reduction in DLCO (93). Additionally, certain non HLA genes appear to be 
associated with a prolonged disease course (37). 
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5. Aims of the study 
Main Aim 
To investigate outcomes, predisposing factors, and early predictors of unfavorable 
outcomes in Juvenile Dermatomyositis patients, and explore how measures for 
disease activity and damage change from early disease stages through follow-up. 
Also we wanted to see how measures for muscular-, pulmonary- and health- 
outcomes in JDM patients differ from that of age- and sex-matched controls from the 
general population. 
Specific aims 
 To investigate the extent of organ damage (applying Myositis damage index) 
in Norwegian JDM patients after median 16.8 years (paper I). 
 To explore how disease activity and disease damage change from first year 
post-diagnosis through follow-up (paper I). 
 To compare muscle strength, physical health and pulmonary function in JDM 
patients with that in 1:1 age- and sex-matched controls from the general 
population (paper II-III) 
 To investigate the extent of MRI detected muscular abnormalities and HRCT 
detected chest abnormalities in JDM patients (paper II-III). 
 To identify early predictors (from the first year post-diagnosis) of organ 
damage, calcinosis and unfavorable muscular outcomes (paper II-II).  
 To see how measures for cumulative organ damage, muscular and pulmonary 
outcomes, correlate with other disease measures at follow-up (paper I-III). 
 To compare HLA-DRB1 allele carriage frequencies in JDM patients with that in 
healthy controls (paper II). 
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6. Study population and Methods 
Study design 
All papers in this thesis have a cross-sectional design (one follow-up examination of 
all patients). In order to identify predictors of the outcomes of interest (findings on the
follow-up examination), a retrospective chart-review was done for all cases (with 
special focus on patient’s characteristics and disease variables the first year post-
diagnosis). In addition, for paper II and III, a case - control design (one age- and sex 
matched control per patient) was used. 
Patients and controls 
Patients 
Inclusion criteria
1. JDM diagnosis in Norway between January 1970 and June 2006  
2. Definite or probable diagnosis of dermatomyositis, according to the Bohan and 
Peter criteria  
3. Onset of symptoms (muscle or skin symptom) before the 18th birthday 
4. Minimum 24 months disease duration (from symptom onset) to the follow-up 
visit. 
5. Age  6 years at follow-up (for paper II and III) 
Exclusion criteria – none
Search strategies 
Patients were identified from the following sources: 
1. Department of Rheumatology, OUH.  
Our department is responsible for the care of children with rheumatic diseases 
in a region comprising 55% of the Norwegian population (2.6 million), and is 
also a referral centre for the remaining parts of the country. 
a) Manual search in the chart archive (1970-1980); this archive contains 
charts from OSR. - 17 patients identified 
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b) Electronic search in the chart archive (1980) 57 patients identified 
- ICD- 8 (1980-1987) 716.0 Dermatomyositis, 716.1 Polymyositis 
- ICD- 9 (1987-1998) 710 Diffuse collagen tissue Disase, 710.3 DM, 710.4 
  polymyositis  
- ICD-10 (1998) M33 Dermatopolymyositis (M 33.0 JDM, M33.1 other  
  DM, M.33.2 PM, M.33.9 unspecified Dermatopolymyositis) 
 
2. The Departments of Pediatrics and Rheumatology at other hospitals 
previously called “regional hospitals” in Norway.  
These hospitals were contacted by letter and asked to refer any JDM patients 
they had seen in the period 1995-2005. - 4 patients identified  
 
By these search strategies, 78 patients were identified, of whom 11 were excluded: 
- 7 because they did not fulfill the Bohan Peter criteria (but underwent a 
diagnostic work-up for JDM).  
- 4 due to “error-coding”. 
 
Thus, 67 of the identified patients fulfilled the inclusion criteria (of whom 63 were 
alive) (figure 1). These patients were evenly scattered from all Norway (relatively to 
population figures). A letter with an invitation to participate was sent all patients (or 
their parents if < 16 years of age); if no answer, one written reminder was sent.  
 
Controls 
Because of the wide age variability of our JDM patients (age 4-54 years at follow-up 
examination), we chose to include controls for parts of the study (papers II and III). 
Patients and controls were matched by age and sex (on individual level), and for 
living in rural or not rural area (on a group level). The controls had their permanent 
address in Oslo or the neighboring county of Akershus. The controls were randomly 
selected from the National Population Register by Ergo Group AS, a company which 
has license to conduct such searches. For each patient, a list of 8-10 possible 
controls was provided. 
A letter with an invitation to participate was sent to the first of the 59 controls 
on the list (or to the parents if aged < 16 years); if no answer a letter was sent to the 
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next selected control etc. No written reminders were sent. Because running out of 
time, at the end of the project, letters was sent to 2-3 individuals at a time. A total of 
243 individuals were contacted (figure 1).  
The main reason to include controls was to investigate the impact of having 
the disease JDM on different outcomes. Since some of our JDM patients also had 
comorbid conditions which could influence the outcomes, we wanted our controls to 
be representative for the general population; not requiring them to be “perfectly 
healthy”. However, we made certain exclusion criteria. All responders (or their 
parents if < 16 years of age), were telephone interviewed before inclusion (by HS).  
Exclusion criteria: 
 Mobility problems 
 Inflammatory rheumatic disease  
 Other autoimmune diseases treated with immunosuppressive agents 
 Heart or lung disease (except for mild asthma) 
 
10 responders were excluded 
- 5 because of presence of exclusion criteria 
- 5 because we identified 2 matched controls for 5 patients; the last responder 
to answer was excluded.  
 
Written informed consent was given from all participants, and from their parents if 
aged < 16 years. The study was approved by the Regional Committee for Medical 
Research. The health directory allowed us to use data on dead patients. 
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JDM PATIENTS CONTROLS 
(Fulfilling inclusion criteria)
 
 
 
         
 
Figure 1. Patients and controls in papers I-III.  
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Core sets 
The core sets for myositis outcome measures, developed by IMACS and PRINTO, 
guided us in the selection of methods for the study.  
 
Table 4: Outcome domains and core sets for IIM / JDM as proposed by IMACS and PRINTO, and 
chosen methods for the present thesis. 
Domains  
      Core sets 
IMACS (75;79) 
All IIM, including JDM 
PRINTO (67;98) 
For JDM 
Present thesis 
 
1. Disase activity    
 Muscle strength MMT CMAS (or MMT)  CMAS + MMT (paper II-III)
 Global disease activity/ 
Extra muscular assessment 
MDAA 
(DAS)* 
DAS 
 (MDAA) 
DAS (papers I-III) 
 Functional ability CMAS or  
Child-HAQ / HAQ 
Child-HAQ CMAS (paper II-III) 
Child-HAQ/ HAQ  
(papers I-III) 
 Muscle enzymes 2 of (CK, ALT, AST, 
LD, aldolase)  
* CK, ALT, AST, LD 
(papers I-III) 
 Physicians global VAS / Likert VAS ‡ (VAS) 
 Patients global VAS / Likert 
 
VAS ‡ (VAS) 
 Health-related quality of life (separate domain) CHQ physical 
summary score 
‡  
2. Disase damage    
 Muscle strength MMT CMAS CMAS + MMT  (paper II-III) 
 Global damage MDI MDI MDI (papers I-III) 
 Functional assessment Child-HAQ / HAQ* Child-HAQ Child-HAQ / HAQ*  
(papers I-III) 
 Growth and development _ Height, weight, 
menses, tanner 
puberty stage 
Height (paper I-III, but not 
as outcome) 
‡ tanner puberty stage 
 Physicians global VAS / Likert VAS / Likert ‡ 
 Patients global VAS / Likert _ ‡ 
3. Health related quality of life    
 SF-36* (short form 36) 
CHQ  
(included in disease 
activity)
SF-36*  
(papers II and III) 
* Recommended used in clinical studies, but not included in the core sets; ‡ Data collected at follow-
up visit, but not included in the present thesis. MDAA = Myositis disease activity assessment tool 
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Data collection
Chart review 
 
    
           Time axis 
                    
            
         
           Data recorded
     
 
Figure 2. Disease variables collected by chart review 
A chart review was carried out in all patients, before the follow-up visit (by HS). If the 
charts were insufficient, other hospitals were contacted for chart copies. Since we 
were especially interested in identifying early predictors of unfavorable outcomes, 
special focus was made on the first year post-diagnosis. Also, the data were found to 
be most complete from these time-points. In addition, complications (e.g. fractures, 
calcinosis and lung disease) and use of mediation any time during disease course 
were recorded. Cumulative prednisolone dose was calculated from the entire disease 
course; if the data were insufficient, the minimum possible dose was registered.  
Methylprednisolone was not included in the cumulative dose. 
 Disease activity (DAS) and organ damage (MDI) were scored retrospectively 
(by HS). No formal intra-rater reliability testing was performed, but to assure 
consistency of the scoring, the first charts to be scored were rescored at the end (by 
HS), with almost identical results.  
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Follow-up visit  
One follow-up visit was carried out of all patients and matched controls in the period 
September 2005 - December 2009 (figure 3).  
  60 (59) patients 
1 ½ day program 
59 controls  
1 day program 
 Sept. 05 – June 08 Dec. 07 – June 09 
 
 
 
    
 
 
 
 
 
 
 
Figure 3. Follow-up assessments in patients and controls
It should be noted that the patients and controls underwent more examinations than listed here (e.g. 
capillaroscopy, bone mineral density and cardiac examinations, but the results of these examinations 
are not included in the present thesis. 
Disase activity 
DAS was chosen for assessment of disease activity (papers I-III). DAS is the 
preferred instrument to measure for global disease activity by PRINTO (98). Also, 
even though not included in the disease activity core set by IMACS, the tool is now 
recommended used in juvenile and adult myositis studies (79). DAS was found to be 
applicable on retrospective data (as opposed to the alternative global disease activity 
tool, MDAA, which was not found suitable for retrospective scoring due to its 
complexity). DAS was scored at the follow-up visit (based on clinical examination) 
Clinical examination (HS) 
e.g. heart and lung 
Muscle strength 
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examinations 
-HRCT -MMT (HS) 
-MRI thigh muscles -CMAS (physiotherapist) 
Laboratory (routine) 
Laboratory (batch) -Muscle enzymes 
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-MSA / MAA -Creatinine 
-HLA DRB1 
Pulmonary function tests 
- Spirometry 
- Diffusion capacity of CO 
- Body plethysmography 
Self reported  Self reported 
-SF-36  CHAQ / HAQ 
-Physical activity 
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and at diagnosis, and 6 and 12 month’s post-diagnosis (by chart review)(figure 2). If 
an item was not mentioned in the charts, a score of 0 = absent was given. DAS 
assesses the extent and distribution of skin involvement and vasculopathic 
manifestations (DAS skin, range 0-9) and muscle weakness and functional status 
(DAS muscle, range 0-11). Thus, DAS total has a possible range of 0-20 (were 0 = 
no activity).  
Global organ damage 
For assessment of global organ damage, MDI was chosen, as recommended by 
IMACS and PRINTO (papers I-III) (67;75). The MDI consists of a total extent of 
damage score, were each symptom or sign is scored present or absent, and then 
summed (range 0-35/37 depending on age and gender). The MDI also consists of 
Visual Analog Scales (VAS) for all 11 organ/systems, and the sum of these scores 
makes the total severity of damage score (range 0-110). For the present thesis, only 
total extent of damage was chosen. Damage is defined as persistent or permanent 
changes, being present for at least 6 months. However, during scoring, we became 
aware that in some patients, evidence of damage during disease course was present 
(e.g. calcinosis), but the damage item was not clinically apparent at the follow-up 
examination. We therefore chose to score damage as cumulative (present during 
disease course) in addition to actual (clinically present at follow-up) (Paper I). Also, 
MDI was scored retrospectively at 6 and 12 months post-diagnosis (by chart review) 
(figure 2). If an item was not mentioned in the charts, it was scored as absent. 
Patient reported outcomes 
HAQ and Child HAQ were used to measure functional ability in patients aged  18 
years and < 18 years, respectively (paper I-III). Child-HAQ is validated for use in JDM 
(99;100). Eight areas of daily activities are scored (range 0-3, were 0 means no 
difficulty with daily activities).  Being a disease specific instrument, CHAQ/HAQ was 
not assessed in matched controls.  
Health related quality of life was measured by the Norwegian version of Short 
Form-36 Health Survey (SF-36) version 1.0, in patients and controls age 12 years 
(101;102) (papers II and III). SF-36 consists of the Physical Component Summary 
score (PCS) and the Mental Component Summary score (MCS); both scores have a 
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mean of 50 in the US population; higher scores indicate better health related quality 
of life.  
Muscle strength 
MMT, a validated tool for muscle strength (66) was assessed in all patients and 
matched controls (by HS) as described in paper II. The MMT-8 version (eight muscle 
versions applied on right side), grade 0-10 was chosen. The muscles included were: 
deltoid, biceps, wrist extensors, quadriceps, ankle dorsiflexors, neck flexors, gluteus 
medius and gluteus maximus. The instructions were adjusted to the patient’s age and 
preformed as shown in the instruction video at IMACS homepage (79). 
 CMAS was used to evaluate muscle strength, physical function and 
endurance in children with JDM (80;81). CMAS is recommended as a tool for muscle 
strength by PRINTO (98), and for functional ability by IMACS; we chose to refer to 
CMAS as a measure of muscle strength/endurance. CMAS has not been validated in 
JDM patient’s aged  18 years. CMAS was performed in all patients and 56/59 
controls by one of two physiotherapists, who were (as far as possible) blinded to 
clinical information.  
The MMT/CMAS examiners were blinded to each others scores, but could not 
be blinded to whether the participants were patient or control. Our definition of 
muscle weakness/reduced endurance (according to MMT and CMAS), was based on 
the scores in the healthy controls, and was defined as: < mean – 2SD of MMT/CMAS 
in matched controls (no established cut-off levels applying these tools are available).  
Pulmonary function test 
Pulmonary function tests (PTF) was performed as described in paper III. All PFT (in 
children and adults) were measured in the same lab (lung function unit), in order to 
ensure the consistency of the data. Spirometry (dynamic lung volumes) and diffusing 
capacity was carried out in all patients and matched controls (applicable in children > 
5-6 years of age)(103). Since the literature have reported restrictive ventilatory 
defects in JDM, body plethysmography (static lung volumes) where included in 
participants aged  9 years (applicable in children > 8-10 years) (103). All lung 
function measurements were performed according to published guidelines (104-106), 
and established cut-offs (< 5th percentile of the predicted values) for lung function 
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impairments were chosen (107). All participants were given written instruction not to 
smoke the last hours before PFT. All DLCO variables were corrected for hemoglobin.  
Radiological Examinations 
MRI thigh muscles 
MRI thigh muscles (T1-weghted and STIR series) were carried out in 58/59 patients 
as described in paper II. All MRI scans were visually and independently scored by 
two experienced radiologist, who were blinded to clinical information; in cases of 
disagreement, consensus was made. Given the long-term follow-up in our patients, 
special focus was made assessing MRI detected damage, which was defined as at 
least one of the following: calcinosis/fibrosis in muscle or fascia (referred to as 
calcinosis), muscle atrophy or muscle fatty infiltration. Since no established scoring 
system for muscular damage is available, a protocol was made by our radiologists 
(EK and EM), based partly on scoring systems previously used 
(83;86;108;109)(Rider, Lisa, personal communication). Due to limited availability and 
practical considerations, MRI scans were not performed in our matched controls.  
HRCT thorax  
HRCT was carried out in 57/59 patients as described in paper III. All HRCT scans 
were visually assessed by one experienced radiologist, blinded to clinical information. 
The scans were evaluated for established HRCT abnormalities (110) according to a 
standardized protocol (paper III). HRCT is regarded a low dose technique, the dose 
of radiation was calculated to 0.1- 0.2 mSvb for children and 0.2-1.0 mSvb for adults. 
For comparison, the annual natural background radiation is 4.5 mSvb (111). HRCT 
scans were not preformed in the matched, healthy controls, due to ethical 
considerations. Also, given the relatively young cohort studied, limited HRCT 
abnormalities would be expected in the general population.  
Laboratory measures
The following blood samples were analyzed consecutive (in routine setting) in 59 
patients and controls: Hemoglobin, muscle enzymes (CK, LD, ASAT and ALAT), ESR 
and creatinine.  
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For detection of ANA, sera from 59 patients were tested at the follow-up visit in 
a routine diagnostic set-up with indirect immunofluorescence using HEp2 or 
HEp2000 cells and fluorescein-labeled anti-human IgG (light +heavy chain). Positive 
samples were titrated and fluorescence patterns interpreted. MSA and MAA were 
analyzed as batch in sera drawn from 59 patients at the follow-up visit, with a 
commercial assay Euroline Myositis Profile (Euroimmune, Lübeck, Germany) 
according to the manufacturer’s instructions The kit contained nitrocellulose strips 
dotted with purified native (Jo-1) or recombinant antigens (Mi-2, Ku, PM-Scl, PL-7, 
PL-12 and Ro52). In addition a separate line blot strip coated with recombinant SRP, 
EJ and OJ antigen in three different dilutions was kindly supplied by Euroimmune as 
a gift. In the first reaction step the strips were incubated with diluted patient sera and 
in the second step the alkaline phosphatase-labelled goat anti-human IgG was 
applied (paper II).  
DNA was extracted from peripheral blood samples in 59 patients (drawn at the 
follow-up visit), and DRB1 genotyping was performed by sequencing, as described in 
paper II. DRB1 data from 898 healthy individuals from the Norwegian bone marrow 
registry (genotyped by the same method), were used as a control group. 
Statistical approach 
These are throughout described in the papers, and will not be repeated. All test used 
in this thesis were two-tailed. In order to explore differences between patients and 
age- and sex-matched controls in paper II-III, paired statistics were chosen. 
Corrections for multiple comparisons were not preformed. 
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7. Summaries of results 
Paper I 
In order to investigate the extent of and risk factors for organ damage and calcinosis 
in longstanding JDM, MDI was assessed in 60 JDM patients after median 16.8 (range 
2-38) years of follow-up. Early disease variables were assessed by chart review, and 
disease activity (DAS) and organ damage (MDI) were scored retrospectively from the 
first year post-diagnosis.  
Cumulative organ damage in at least one organ (MDI>0) was found in 90% of 
the patients at follow-up. Damage occurred most often in the cutaneous (77%), 
muscular (65%) and skeletal (57%) domains; 47% had calcinosis during disease 
course. Disease activity decreased during the first year post-diagnosis, whereas 
cumulative organ damage increased from one year post-diagnosis through follow-up. 
Early predictors of organ damage were high disease activity (DAS) and damage 
present (MDI) 6 months post-diagnosis. Follow-up time also correlated with MDI. 
Calcinosis was predicted by male gender and high disease activity 6 months post-
diagnosis.  
These results show that the majority of JDM patients have organ damage after 
median 16.8 years, and that sustained early disease activity predicts such damage.  
Paper II 
In order to investigate JDM muscular outcome and risk factors for unfavorable 
outcomes, muscle strength/endurance (MMT and CMAS), laboratory tests (muscle 
enzymes and creatinine) and health status (SF-36) were assessed in 59 JDM 
patients and 59 age- and sex-matched controls from the general population. In JDM 
patients, MRI scans of the thigh muscles were performed. Early disease variables 
were assessed by chart review. In order to identify predisposing factors for JDM, 
HLA-DRB1 alleles were determined in all patients and 898 healthy controls. 
Muscle strength/endurance and physical health was lower in patients than 
controls. Muscle weakness/reduced endurance were found in 31% according to 
CMAS and 42% according to MMT. MRI detected muscular damage was found in 
52% of the patients, and included atrophy, fatty infiltration and calcinosis. The 
outcomes in JDM patients were predicted by high muscular disease activity (DAS) 
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and muscle damage present 1 year post-diagnosis. Patients had increased HLA-
DRB1*0301, and supports this allele as a predisposing genetic factor. Also, a novel 
association with DRB1*1401 was found in the patients, which needs to be confirmed 
in larger datasets. 
These results show that JDM patients many years after diagnosis have more 
muscle weakness and poorer physical health compared to the general population, 
and that sustained early disease activity predicts an unfavorable muscular outcome.  
Paper III 
In order investigate pulmonary outcome in JDM, pulmonary function (spirometry, 
measurements of gas diffusion and body plethysmography) was assessed in 59 JDM 
patients and 59 age- and sex-matched controls from the general population; also 
HRCT scans were carried out in the JDM patients.  
 JDM patients had smaller lung volumes (lower total lung capacity, TLC) and 
lower DLCO than controls. Of JDM patients, a restrictive ventilatory defect was found 
in 26%, reduced pulmonary diffusion capacity in 49% and HRCT abnormality in 37%.  
A low TLC was associated with HRCT abnormalities. HRCT abnormalities were 
associated with restriction, cumulative organ damage and poorer self reported health 
status at follow-up. None of the pulmonary outcomes correlated with muscle strength. 
Early disease activity was not found to be predictor of unfavorable pulmonary 
outcome.  
These results show that many JDM patients have impaired lung function and 
HRCT abnormalities after median 16.8 years of follow-up. Although the findings in 
many patients were subclinical, our findings highlight the systemic nature of JDM.  
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8. General Discussion 
The first part of the discussion will focus on the representativeness of the patients 
and controls. Then, the outcomes will be discussed, according to the proposed core 
sets for myositis outcomes; disease damage, disease activity and patient reported 
health status. Muscular and pulmonary outcomes will be discussed separately, since 
muscle strength is included in both activity and damage core sets, whereas 
pulmonary assessment is not included in any core sets. At last, the early predictors of 
all the outcomes will be discussed. 
The representativeness of the study populations 
JDM patients  
The selection of patients for our study was based on all Norwegian JDM cases we 
were able to identify from hospital records in the given time period (retrospective
inception cohort). The main search for JDM patients was done at the Department of 
Rheumatology at OUH (including charts from OSR), which is a tertiary center. In 
addition, some patients treated at the other 3 major hospitals (previously called 
Regional hospitals) the last 10 years were recruited. Our patients were evenly 
scattered from all Norway, relatively to population figures. Due to the rareness of the 
disease, we did not attempt to identify patients who had exclusively been treated at 
local hospitals or by practitioners. Thus, our patient cohort is referral based, and not 
population based.  
The 67 patients identified from 1970-2006, correspond to an average annual 
incidence of JDM in Norway of 1.8 / million children < 18 years, which is slightly less 
than the incidence reported in 2 population based studies (1.9 - 3.2 per million 
children) (19;20). The 21 identified patients diagnosed from 2000-2006, correspond 
to an average annual incidence of 2.9 per million children. Taken together, we might 
be biased towards more severe cases, especially for the earliest diagnosed patients, 
but our figures support that the majority of Norwegian JDM patients from this time 
period actually were identified. A major strength of our study is that all living identified 
patients could be localized (due to the Norwegian population register), and that 95% 
of those chose to participate in the study. Some other outcomes studies have been 
limited to patients still followed because of a JDM diagnosis (prevalence cohort) (70).  
37 
 
  
The female predominance, duration of untreated disease and onset features 
are comparable with other JDM cohorts, whereas the age at diagnosis is slightly 
higher in our cohort (tables 2+5). Also, our study support HLA DRB1*03 as a 
predisposing genetic factor (32;36). 
Table 5. Patients and disease characteristics at onset in selected JDM cohorts 
 Ramanan 
2002 (9) 
Pachman 
2006 (112)  
 
McCann 
2006 (8)   
Sato  
2009 (113) 
Rider  
2009 (114) 
Ravelli 
2010 (115) 
Sanner  
papers I-III 
Country 
Source 
Canada 
Hospital 
USA 
Hospital 
UK 
Registry 
Brazil 
Multi 
center 
registry 
12 centers, 
USA, 
Canada and 
Europe 
27 centers,  
5 countries,  
2 continents 
Norway 
Hospital 
Patients included 
 
105 JDM 166 JDM 175 JDM 189 IIM 
(173 JDM) 
143 IIM 
(134 JDM) 
446 JDM 60/59  JDM 
Time of diagnosis 1991-
2002 
1994-1999 Before 
2000 retr 
 1993-2002 1980-2004 1970-2006 
European /white/ 
Caucasian % 
 74 83 65 65  97 
Females % 68 66 69  66 66 60 
Age at onset, 
years (range) 
 7.5 (3.8) Mean 7.7 
(1-16)  
Median  7  
 
Mean 6.9  
(0.9-17.8) 
Median  7.7 
(1.4-17.3) 
Age at diagnosis, 
years (range) 
    Median 6   Median 8.5 
(2.2-19.2) 
Untreated 
disease, months 
(range),  
 Median 4  
(0-98) 
Median 3 
(0-118) 
 Median 3   Median 4  
(0-119)  
Weakness, % 95 92  88 96  85 97  
Heliotrope, % 83   84  62 78  
Gottron, % 91  88 83  73 78  
If not otherwise stated, these studies have used age limit < 18 years at diagnosis. *age limit < 16 years 
at diagnosis, † age limit not specified 
Matched controls 
The randomly selection of our matched controls from the Norwegian population 
register, is a strength of our study (paper I and II). The age at follow-up is highly 
variable in our patient cohort. Since the outcome variables studied (e.g. pulmonary 
function and muscle strength), are highly dependent on sex and age, we wanted to 
reduce the influence of these factors as possible confounders, and chose a case - 
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control design matching for age and sex. We selected the controls from the “general 
population”, and we thus believe that the detected differences found between 
controls and patients mainly are due to the presence of JDM. The acceptance rate of 
the controls was 28%; how this influences the representativeness of the controls we 
do not know, since we have no information about the non-responders. Our controls 
had their address in Oslo and the neighboring county of Akershus as opposed to the 
patients who were settled in all Norway. The population in Norway is relatively 
homogeneous; also the percentage of European participants was identical in the 
patient and matched control group. One could suspect that those who volunteer to 
participate in studies are healthier than others. However, our controls are comparable 
with the general Norwegian population < 55 years, with regards to dally smoking 
habits (~ 20%) (116).  
Disease damage 
All papers included in this thesis, showed that a majority of JDM patients develop 
organ damage during disease course. This is supported by the findings that 90% of 
our patients had signs of organ damage in at least one organ (MDI>0) (paper I), that 
the majority of patients has organ specific damage like muscular damage on MRI 
(paper II) and impairments of pulmonary function and/or HRCT changes (paper III).  
The impact of follow-up time on accumulated damage 
When assessing any damage item accumulated from disease onset (e.g. calcinosis 
or pulmonary fibrosis), the frequency of damage will increase with the length of time a 
cohort has been studied (74). This is supported by our findings that MDI and MRI 
detected muscle damage correlated with follow-up time, and that the mean time for 
development of calcinosis was 2.5 years from disease onset (paper I). In order to 
make studies addressing JDM organ damage comparable, evaluation should ideally 
cover a minimum follow-up period for all patients (for example at least 2 after 
symptom onset) and include only patients who have reached this end-point. Patients 
followed shorter, may still be subjected to develop organ damage (from ongoing 
disease activity, medication or comorbid conditions). Some of the reported outcome 
studies include patients followed less than 1 year. We have the longest follow-up time 
reported (114;115). This also implies that we have included patients who were 
diagnosed in a period were the treatment regimes were less aggressive, and thus 
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may have been subjected to more damage, compared to other recent published 
studies. 
Comparison of studies assessing organ damage by MDI 
No study applying the MDI tool was available when our study was initiated. Then, 
during a three months period, two multinational, multicenter, studies addressing JDM 
organ damage in addition to our paper I, were published (114;115)(Table 5). Damage 
detectable in at least one organ system was found in 73% of juvenile IIM (Rider, 
extent score), 69% of JDM patients (Ravelli, severity score) and 90% of JDM patients 
(paper I, extent score). The follow-up time in the two multinational studies (~ 7 years) 
is less than half of our study (~ 17 years), which might explain some of these 
differences, as previously discussed.  
The IMACS study is primarily a validation study, and the representativeness of 
the cohort (recruited from 12 centers in 2 continents) is not discussed. Also, the MDI 
was exclusively scored based on retrospective data, whereas we scored damage 
based on chart review and clinical examination. It is possible that mild changes (e.g. 
cutaneous scarring) were missed if not specifically looked for. In our study, most 
patients with MDI extent of damage = 1, only had cutaneous scarring. Interestingly, in 
the IMACS study, damage was found in 98% of the adult IIM patients. If this is due to 
more comorbid disease in adults (which is also included in MDI), difference in how 
the method was applied (adult patients were all from US), or if the adult onset 
disease actually leaves patients with substantial more damage, remains to be settled. 
In all these studies, the 3 organs with most often scored damage were (in 
declining order) skin, muscle and skeletal, which emphasize that skin and muscle are 
organs most often affected in JDM. We found higher percentages with damage in all 
these organs compared to Rider and Ravelli. However, these figures are not directly 
comparable, since we chose to present the extent of damage score also for the 11 
organs/systems, as opposed to Rider and Ravelli who used VAS severity score. We 
scored damage based on chart review 6 and 12 months post diagnosis, and found 
extent easier to score than severity. Rider validated MDI, and found that the MDI 
severity and extent scores had a high correlation (rs = 0.87), and thus may be 
redundant measures. However, the severity score showed a stronger correlation with 
other disease measures than the extent score. Indeed, some of the correlations 
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between MDI and other disease measures were higher in IMACS study than in our 
study, which may be explained by the fact that we used the extent score. 
On the other hand, the scores for the specific items (absent/present) are 
directly comparable, and our patients had more damage especially in the muscle 
items (table 5), which will be further discussed under muscular outcome. Calcinosis 
was also ore often scored in our cohort, 47% cumulative and 37% actual as opposed 
to ~ 25% in the Ravelli/Rider studies (114;115). However, in the Rider study, it was 
not specified if the scoring was cumulative. The frequency of calcinosis in our cohort 
is comparable with some other studies and higher than in others (68) (table 3). This 
may indicate that we are biased towards severe cases. However, the argument of 
follow-up time is also important here; e.g. in the Sallum study, 11/35 (31%) of the 
patients had a follow up time of 2.5 years or less compared to 5% in our study.  
Joint contractures were also more frequently scored in our cohort, 53% 
cumulative and 45% actual, compared to 18-27% (Ravelli/Rider). We scored 
contractures as fixed limitation in the normal range of motion (as recommended in the 
glossary term). How this was interpreted in the other studies, we do not know, but we 
cannot rule out that the discrepancy is due to in how the method was applied. Also, 
joint contractures may be secondary to calcinosis, which may contribute to the high 
percentage in our study. Half of our patients had arthritis during disease course 
(paper I), which is in accordance with a recent published study (117), and might 
contribute to this high percentage. On the other hand, we did not find any damage in 
the ocular system, but it should be noted that we did not specifically test vision.  
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Table 5. JDM outcome studies measuring organ damage by MDI 
 Rider for IMACS (114) Ravelli (115)† Sanner (paper I) 
Patients included 143 IIM  
(134 JDM) 
96 adult IIM * 
(38 DM) 
462 JDM 59 JDM 
Scoring of MDI 
 
Retrospective 
 
Retrospective Retr + follow-up 
cumulative 
Retr + follow-up
cumulative 
Follow-up time, years (range) Median 6.8  
(4.3-8.7) 
Median 5  
(3.3-8.6) y 
Mean 7.7 Med 16.8  
(2.0 – 38.1) 
Extent of total damage >0, %  73 98 63 90 
Muscle Muscle atrophy 11 83 24 35 
Muscle weakness 27 74 11 47 
Muscle dysfunction 23 84 16 42 
Skeletal Joint contracture 27 7 18 53 
Osteoporosis 11 12 6 8 
Avascular necrosis 4 6  5 
Arthropathy 4 18  2 
Coetaneous Calcinosis 26 16 24 47 
Alopecia 5 15  0 
Cutaneous scarring 30 27 44 63 
Poikiloderma 4 8  2 
Lipodystrophy 11 2 10 17 
Gastro  
intestinal 
Dysphagia 13 53 5 7 
GI dysmotility 8 37  3 
GI infarction / resection 1 1 2 0 
Pulmonary Dysphonia 15 21  3 
Impaired lung function 4 49  8 
Pulmonary fibrosis 1 28  5 
Pulmonary hypertension 1 4  0 
Cardio-
vascular 
Hypertension 3 29  7 
Ventricular dysfunction 1 21  2 
Angina NA 1  3 
Myocardial infarction NA 2  3 
Peripheral 
vascular 
Tissue pulp loss 1 1  7 
Digit loss 0 1  3 
Thrombosis 1 3  0 
Claudication NA 3  0 
Endocrine Growth failure 14 NA 8 10 
Hirsutism 8 2 10 20 
Irregular menses 1 3  20 
Amenorrhea 0 3  8 
Diabetes 1 16  0 
Ocular Cataract 2 10 2 0 
Vision loss 1 2  0 
Infection Chronic 3 14  0 
Multiple 3 2  13 
Malignancy 0 3  2 
For the specific damage items, numbers are % of total with positive scores  
* adult patients from one center in USA, † many items not given, ‡ Infertility, sexual dysfunction and delay in 
sexual characteristic not listed, due no missing data in all studies. 
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Disease activity 
In the present thesis, we did not use disease activity as a primary outcome measure, 
but focused on the change in disease activity from the first year post-diagnosis 
through follow-up (paper I), and also used early disease activity as a predictor for 
unfavorable outcomes (paper I-II). The level of the DAS scores at diagnosis and 
during the first year post-diagnosis is comparable with previous studies (58;118;119). 
We found that DAS skin decreased less compared to DAS muscle during the first 
year. This is in accordance with a recent study showing that improvement of skin 
signs seems to be a slow process in parallel with the regeneration of capillary end 
row loops, whereas muscle inflammation responds more quickly to treatment (58). A 
register based study, has also showed that more patients have sustained rash than 
muscle weakness one year after the diagnosis (8). We believe this supports the 
validity of our retrospective scoring of DAS. 
At follow-up, DAS was scored based on clinical examination. A problem with 
applying DAS after such a long follow-up time, is that DAS does not distinguish 
between muscle weakness due to disease activity or damage (DAS scoring 
instructions on IMACS homepage) (79), (Pachman, Lauren M, personal 
communication). Also, atrophic changes are included in DAS skin. Thus, it might be 
that disease damage interferes with disease activity when DAS is applied after a long 
follow-up time. This is supported by that only 30% of our patients used immune 
suppressive medication at follow-up, whereas > 60% had a DAS > 3 (paper I). Also, 
MDI and DAS at follow-up correlated (rs= 0.45) (paper I). Interestingly, Ravelli et al 
found that more patients had disease activity after mean 7.7 years follow-up 
according to DAS than according to MDAA, 61% vs. 41%.  
Most JDM clinical studies divide their patients into 3 disease courses 
(monocyclic, polycyclic and chronic continues) or non-unicyclic or unicyclic course 
(58). However, there are no established remission criteria for JDM. Thus, the 
definition for ongoing disease (chronic or non-unicyclic disease courses), varies 
between different studies. Examples of definitions are no detectable clinical, 
biochemical or radiographic evidence of disease activity and off all medication (52), 
no evidence of rash, muscle weakness or arthritis, normal muscle enzymes and off 
all medication for 6 months (120) and DAS  3 (58). In other studies, duration of 
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active disease has been calculated without defining disease activity (114;115). 
Facing problems with the definition of active disease and thus disease courses, we 
chose not to divide or patients according to these parameters. 
Patient reported health status 
Table 6. Functional disability in JDM patients 
  Huber, 2000 Sanner 2009* Ravelli 2010 
No of patients 67 60 339  
Country Canada Norway Multinational 
Follow-up time median 7.2 median 16.8 mean 7.7  
No impairment, % of total †, 72 60 59 (Europe 62) 
Child-HAQ  1, % of total 8 3 
Child-HAQ > 1.5, % of total  0 7 (Europe 5)  
    
* HAQ was used in patients > 18 years; † Child-HAQ/HAQ = 0 
The majority of our patients had no physical disability as measured by HAQ/Child-
HAQ, which is in accordance with previous studies (52;115). However, we had fewer 
patients with severe impairments than reported in these studies. Child-HAQ/HAQ is 
included in both disease activity and disease damage core sets. In our study, child-
HAQ/HAQ scores, showed a positive correlation with cumulative damage (paper I), 
MRI detected muscle damage (paper II), and a negative correlation with muscle 
strength/endurance measured by CMAS and MMT (paper II). Child-HAQ/HAQ scores 
also showed a positive correlation with HRCT detected abnormality, including HRCT 
detected ILD and calcinosis (paper III). These findings supports that our outcomes 
are reflected by patients own perception of the disease. SF-36 PCS was lower in 
patients than controls supporting impaired physical health related quality of life in the 
patients. However, no significant difference was found between patients vs. controls, 
when analyzing patients diagnosed after 1990 separately (paper II).  
Muscular outcome 
In JDM, muscle weakness may be due to both damage and activity, thus MMT and 
CMAS are included in both disease activity and damage core sets. Our findings that 
a substantial portion of patients had muscle weakness at follow-up, is in accordance 
with Ravelli, who used the same methods to asses muscle strength (CMAS and 
MMT-8 with identical subsets), a method that recently has been recommended (121). 
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Our patients had muscle strength comparable to slightly stronger than in the Ravelli 
study. However, the proportion of patients being though to have muscle weakness 
due to damage was 4 times higher in our study (47 vs. 11%). This discrepancy may 
have several explanations. First, according to MDI, the magnitude of muscle 
weakness necessary in order to be scored is not defined; thus the tools may have 
been applied differently. Also, we might to a higher degree have interpreted muscle 
strength impairment to be due to disease damage and not disease activity, especially 
due to our lengthy follow-up time.  
Since we based our cut-off levels for muscle weakness on scores of our 
matched controls, our cut-offs were lower than those used by Ravelli; when applying 
these cut-off levels on our patients, we actually found reduced muscle strength in 12-
29% of the controls (MMT and CMAS, respectively)(paper II). However, we do not 
believe that we have identified the ideally cut-offs for muscle weakness applying 
these tools, for that we would have needed a higher number of controls with a 
blinded design for patients/controls.  
MRI scans were carried out in patients. We included calcinosis in muscle 
and/or fascia in MRI detected damage, since obviously calcinosis is damage, and 
when present in these layers, may reduce muscle strength. However, we are aware 
that MRI is not the preferred method to detect calcinosis, since it might be difficult to 
distinguish between calcinosis and fibrosis (also being damage), and we did not have 
radiographic confirmation of density to prove that these changes were calcinosis. 
However, we believe that the high correlation between “MRI detected muscle 
damage” and MDI total (rs > 0.7), supports the validity of our scoring.  
We found that both CMAS and MMT correlated with MDI muscle damage, 
whereas only CMAS correlated with MRI detected muscle damage. This may indicate 
that CMAS to a higher degree than MMT measures damage, which is supported by 
data from the Ravelli study; Latin American patients had more damage (MDI) and 
more CMAS impairment, whereas MMT scores comparable. This highlights the 
importance of measuring muscular endurance. Another tool for measuring 
endurance, the Functional index has been developed (122;123), but needs special 
equipment and has not been validated in children. 
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Pulmonary outcome 
Measures for pulmonary outcomes are not included in the core sets for disease 
activity or damage. However, the pulmonary system is included in MDI. In our study, 
17% were found to have pulmonary damage (by MDI) (paper I), a result which is 
comparable with one study (114) and higher than another (115). Even though 
previous studies have reported a high frequency of restrictive defects in JDM (72;93), 
the finding of 25-50 % of the patients having restrictive ventilatory defects or low 
DLCO after median 16.8 years follow-up, was surprising. Our assessment of 
restriction was done by body plethysmographic assessed TLC, which is the preferred 
method. Also, we showed that low lung volumes were associated with HRCT 
abnormalities.  
Pulmonary impairment did not differ between patients diagnosed before or 
after 1990, but we are aware that we might be underpowered to show such 
associations. We were neither able to find any correlation between pulmonary 
function and muscle strength; nor did we identify any early predictors for the 
pulmonary outcomes. This might indicate that the processes affecting the lungs may 
differ from the other disease processes.  
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Prognostic factors for unfavorable outcomes 
A major finding of this thesis, is the identification of sustained early disease activity 
(measured by DAS 6 and 12 months post-diagnosis), as early predictors of calcinosis 
and cumulative organ damage (paper I), and for MRI detected muscular damage and 
decreased muscle strength/endurance at follow-up (paper II). 
 Identification of early predictors of unfavorable outcomes is obviously 
important. Growing evidence suggest that sustained early disease activity is 
associated with unfavorable outcomes (Table 7). There is some data suggesting that 
onset features is associated with unfavorable outcomes (58;115), even though most 
studies have not shown such associations)(52)( present thesis). One other study 
have evaluated disease features the first year post-diagnosis, and found that skin 
rash and nailfold abnormalities were associated with long time to remission, but not 
with disease course (120). Then again, a long duration of active disease has been 
found to predict different damage items (115). However, chronic disease course is 
the predictor most often associated with unfavorable outcome. One can speculate 
that our findings of sustained disease activity and high MDI during the first year post-
diagnosis are markers for a chronic disease course. However, that assumption is not 
supported by a recent study (58).  
Patients’ characteristics, especially female gender has recently been 
associated with unfavorable outcomes. Our finding of male gender as a predictor of 
calcinosis should thus be interpreted with caution. We were not able to identify 
treatment variables as predictors, which might be due to confounding by indication 
(seriously affected patients are treated more aggressively) (118). Also, duration of 
untreated disease has been predictive of calcinosis (58); in our study, duration from 
symptom to diagnosis showed a weak, univariate, but not multivariate association. 
This may have been due to limited sample size. At last, it is important to be aware of 
that a statistical correlation not necessarily means a casual connection, and that 
predictors can be applied at group level, and cannot necessarily predict the outcome 
in a single patient.  
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Table 7. Identified early predictors of unfavorable JDM outcomes 
Predictor Outcome Study  
Female Muscle weakness (MMT) Ravelli 2010, Sanner (paper II) 
  Muscle weakness (CMAS) Ravelli 2010  
  Functional disability (Child-HAQ) Huber 2000, Ravelli 2010   
Male Calcinosis Sanner (paper I) 
 
Young age at onset Muscle weakness (CMAS) Ravelli 2010  
 
Delayed treatment Calcinosis Bowyer 1983, Fisler 2002,  
   Pachman 1998/2005, Tabarki 1998 
Long duration untreated disease Non-monocyclic course Christen-Zaech 2008   
   
Inadequate treatment Calcinosis Bowyer 1983, Fisler 2002 
 
Insidious disease onset Continued disease activity (DAS, MDAA) Ravelli 2010 
     
Skin symptoms at onset Cutaneous damage (MDI) Ravelli 2010 
  Muscle weakness (CMAS) Ravelli 2010 
  Chronic disease course Christen-Zaech 2008 
Skin or GI ulcerations Organ damage (MDI) Rider 2009 
 
Muscle weakness at onset Muscle damage (MDI) Ravelli 2010 
 
Muscle biopsy findings* Chronic disease course Crowe 1982, Wargula 2006, Miles 2007 
    
Anti p155/140 Cutaneous involvement / lipodystrophy  Gunawardena 2008, Bingham 2008  
Anti p 140 Calcinosis Gunawardena 2009 
 
Gottron 3/6 months Long time to remission Stringer 2008 
Nailfold abnormalities, 6 months Long time to remission Stringer 2008 
 
High DAS total 6/12 months Organ damage (MDI) Sanner (paper I) 
  Calcinosis Sanner (paper I) 
  MRI detected muscle damage Sanner (paper II)  
 
High DAS muscle, 12 months Low CMAS Sanner (paper II) 
 
High MDI, 6/12 months Organ damage Sanner (paper I) 
    
MDI muscle damage, 12 months Low MMT Sanner (paper II) 
  MRI detected muscle damage Sanner (paper II)  
 
Long duration active disease Organ damage (MDI) Rider 2009 
  Skin damage (MDI) Ravelli 2010 
  Calcinosis / Lipodystrophy Ravelli 2010 
  Skin damage (MDI) Ravelli 2010   
 
Chronic disease course Calcinosis Bowyer 1983, Ravelli 2010 
  Functional disability (Child-HAQ) Huber 2000, Ravelli 2010 
  Organ damage (MDI) Ravelli 2010 
  Muscle weakness (MMT) Ravelli 2010 
  Muscle weakness (CMAS) Ravelli 2010 
  Disease activity (DAS/MDAA)  Ravelli 2010 
 
Studies included: Ravelli 2010 (115), Huber 2000 (52), Bowyer 1983 (45) , Fisler 2002 (53), Pachman 1998 (124), Pachman 
2005 (27), Tabarki 1998 (74), Christen-Zaech 2008(58), Rider 2009 (114), Crowe 1982 (125), Wargula 2006 (126), Miles 2007 
(127), Gunawardena 2008 (128), Bingham 2008 (129), Gunawardena 2009 (130), Stringer 2008 (120);  
*arteropathic changes, capillary loss. 
48 
 
  
9. Main conclusions 
 90% of JDM patients had cumulative organ damage in at least organ, median 
16.8 years after disease onset 
 Organ damage was most frequently found in the cutaneous, muscular and 
skeletal domains 
 Disease activity decreased during the first year post-diagnosis, whereas 
cumulative organ damage increased from 1 year to follow-up. 
 JDM patients had lower muscle strength and physical function compared to 
age- and sex-matched controls from the general population.  
 MRI detected muscle damage was found in ~ 50% of the patients, and 
correlated with cumulative organ damage, and muscle strength/endurance. 
 High disease activity and high cumulative damage / muscle damage 6 and 12 
months after JDM diagnosis, were identified as early predictors of calcinosis, 
cumulative organ damage, muscle weakness and MRI detected muscle 
damage at follow-up.  
 JDM patients had lower gas diffusion and smaller lung volumes than controls; 
restrictive ventilatory defects were found in ~25% and reduced DLCO in ~ 50% 
of the patients.  
 HRCT abnormalities was found in 37% of the patients, and included calcinosis 
in the chest wall in 14%, interstitial lung disease in 14% and small airways 
disease in 15%. HRCT abnormalities were associated with restrictive 
ventilation defects, cumulative organ damage and patient reported outcomes. 
 The pulmonary involvement was mostly subclinical and difficult to predict, but 
highlights the systemic nature of JDM.  
 HLA-DRB1* 0301 was confirmed to be a predisposing factor for JDM in 
Norwegian JDM patients, and HLA-DR*1401 was identified as a possible 
novel predisposing factor.  
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Concluding remarks 
We have answered some aspects of the question “what is the prognosis of 
JDM”, by looking at Norwegian patients. We believe that our findings can be 
generalized to other countries were the treatment regimes are comparable. Increased 
knowledge about JDM outcomes is important for the patients and their parents, and 
for the pediatric rheumatologist and other health professionals working with these 
patients. However, it should be further debated, what are the best methods to 
measure long-term outcome, since the core sets developed for outcomes in clinical 
trials might not be ideal for assessing long term outcome.  
Our identification of sustained early disease activity as a predictor for 
unfavorable outcomes, is in accordance with other studies, and might be useful in 
clinical practice. However, one should be aware that such predictors not necessarily 
can be applied in a single patient. Our findings of pulmonary impairment should 
warrant clinicians about the possibility of pulmonary complications also in the juvenile 
form of DM.  
Given the rareness of this disease, we welcome the ongoing international 
collaborations, making large prospective natural history studies possible. We do 
however believe that single center studies like ours, have a place in carefully 
examining patients, by one/few investigator(s). Recently, there have been important 
new developments in immunology and thus treatment rationale for JDM. International 
collaborations are also important in exploring the effects of modern treatment on 
outcomes. Since our study is not mechanistic in nature, we intend to explore 
mechanisms behind our findings, like micro vascular changes, cytokine profiles, 
autoantibodies and muscle biopsy finding, in future studies.  
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